An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-8527 in Participants With Mild and Moderate Hepatic Impairment
Latest Information Update: 03 Mar 2026
At a glance
- Drugs Alimatravir (Primary)
- Indications Liver cancer
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 27 Feb 2026 Actual Primary Completion date changed to 13 Feb 2026.
- 27 Feb 2026 Status changed from active, no longer recruiting to completed.
- 14 Jan 2026 Planned End Date changed from 7 Jan 2026 to 4 Feb 2026.